5 Healthcare Stocks to Buy Now According to Billionaire Louis Bacon

Page 3 of 3

1. Moderna, Inc. (NASDAQ:MRNA)  

Moore Global Investments’ Stake Value: $73.12 million

Moore Global Investments’ 13F Portfolio: 1.11% 

Number of Hedge Fund Holders: 49

Moderna, Inc. (NASDAQ:MRNA) deals in the development of transformative medicine based on messenger ribonucleic acid (mRNA). It offers a range of vaccines, including its popular Covid-19 dose with an efficacy rate of 94.1% in a large-scale, ongoing clinical trial.

On December 6, Cowen analyst Tyler Van Buren initiated coverage of Moderna, Inc. (NASDAQ:MRNA) with a ‘Market Perform’ rating and a price target of $250. The analyst noted that demand for the company’s Covid vaccine would be robust for the foreseeable future, with the company positioned to address any emerging variants that might be of concern.

Investors are loading up on the vaccine maker, with 49 hedge funds reporting ownership of stakes in Moderna, Inc. (NASDAQ:MRNA) at the close of the third quarter. In contrast, 37 hedge funds held stakes in the company a quarter ago.

Investment management firm Carillon Tower Advisers mentioned in its Q3 investor letter. Here’s what the fund said:

Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The stock proved to be an impressive contributor once again in the quarter, as investors continue to evaluate the potential for future growth driven primarily by the firm’s revolutionary COVID-19 vaccine. Strong global demand for the vaccine may persist for the foreseeable future in order to maintain immunity as well as provide protection against any additional future variants. The potential for the firm’s mRNA technology to be used in a number of other use cases, specifically influenza, could also provide an additional tailwind for future growth.”

You can also take a look at 10 Best Tech Stocks to Buy Right Now Under $10 and 10 Best Software Stocks To Buy Now

Page 3 of 3